# <sup>1</sup> Methodological Challenges using Routine Clinical

- <sup>2</sup> Care Data for Real-World Evidence: a Rapid
- <sup>3</sup> Review utilizing a systematic literature search and

# 4 focus group discussion

5

| 6  | Michelle Pfaffenlehner <sup>1,2*</sup> , Max Behrens <sup>1,2</sup> , Daniela Zöller <sup>1,2</sup> , Kathrin Ungethüm <sup>3,4</sup> , Kai                   |
|----|---|
| 7  | Günther <sup>3,4</sup> , Viktoria Rücker <sup>4</sup> , Jens-Peter Reese <sup>4</sup> , Peter Heuschmann <sup>3,4,5</sup> , Miriam Kesselmeier <sup>6</sup> , |
| 8  | Flavia Remo <sup>6</sup> , André Scherag <sup>6</sup> , Harald Binder <sup>1,2</sup> , Nadine Binder <sup>7,2</sup> – for the EVA4MII project                 |
| 9  | <sup>1</sup> Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Centre – University of   |
| 10 | Freiburg, Freiburg, Germany   |
| 11 | <sup>2</sup> Freiburg Centre for Data Analysis and Modelling, University of Freiburg, Freiburg, Germany   |
| 12 | <sup>3</sup> Institute for Medical Data Sciences, University Hospital Würzburg, Würzburg, Germany   |
| 13 | <sup>4</sup> Institute for Clinical Epidemiology and Biometry, University Würzburg, Würzburg, Germany   |
| 14 | <sup>5</sup> Clinical Trial Centre, University Hospital Würzburg, Würzburg, Germany   |
| 15 | <sup>6</sup> Institute of Medical Statistics, Computer and Data Sciences, Jena University & Jena University   |
| 16 | Hospital, Jena, Germany   |
| 17 | <sup>7</sup> Institute of General Practice/Family Medicine, Faculty of Medicine and Medical Centre - University of  |
| 18 | Freiburg, Freiburg, Germany   |

19 \*corresponding author: michelle.pfaffenlehner@uniklinik-freiburg.de

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

### 20 Abstract

#### 21 Background

The integration of real-world evidence (RWE) from real-world data (RWD) in clinical research is crucial for bridging the gap between clinical trial results and real-world outcomes. Analyzing routinely collected data to generate clinical evidence faces methodological concerns like confounding and bias, similar to prospectively documented observational studies. This study focuses on additional limitations frequently reported in the literature, providing an overview of the challenges and biases inherent to analyzing routine clinical care data, including health claims data (hereafter: routine data).

#### 29 Methods

We conducted a literature search on routine data studies in four high-impact journals based 30 on the Journal Citation Reports (JCR) category "Medicine, General & Internal" as of 2022 and 31 three oncology journals, covering articles published from January 2018 to October 2023. 32 33 Articles were screened and categorized into three scenarios based on their potential to provide meaningful RWE: (1) Burden of Disease, (2) Safety and Risk Group Analysis, and (3) 34 35 Treatment Comparison. Limitations of this type of data cited in the discussion sections were extracted and classified according to different bias types: main bias categories in non-36 randomized studies (information bias, reporting bias, selection bias, confounding) and 37 additional routine data-specific challenges (i.e., operationalization, coding, follow-up, missing 38 data, validation, and data quality). These classifications were then ranked by relevance in a 39 40 focus group meeting of methodological experts. The search was pre-specified and registered in PROSPERO (CRD42023477616). 41

#### 42 Results

In October 2023, 227 articles were identified, 69 were assessed for eligibility, and 39 were included in the review: 11 on the burden of disease, 17 on safety and risk group analysis, and 11 on treatment comparison. Besides typical biases in observational studies, we identified additional challenges specific to RWE frequently mentioned in the discussion sections. The

focus group had varied opinions on the limitations of Safety and Risk Group Analysis and
Treatment Comparison but agreed on the essential limitations for the Burden of Disease
category.

#### 50 Conclusion

This review provides a comprehensive overview of potential limitations and biases in analyzing routine data reported in recent high-impact journals. We highlighted key challenges that significantly impact analysis results, emphasizing the need for thorough consideration and discussion for meaningful inferences.

55 Keywords: rapid review, limitation, bias, routine clinical care data, real-world evidence, EHR

56

### 57 Background

58 Real-world evidence (RWE) derived from real-world data (RWD) becomes increasingly 59 important to support clinical evidence. The growing availability of such data opens up new 60 research opportunities to improve our understanding of clinical practice. A recent definition of 61 real-world data includes data sources such as routine clinical care data, frequently called 62 electronic health records (EHRs), disease-specific registries, administrative data, such as 63 claims data or death registries, and data collected through personal devices [1–4].

This review is limited to routine clinical care data (hereafter: routine data) derived from the 64 health care system, such as EHR and administrative data including insurance and claims data. 65 66 We focus on methodological challenges and biases that researchers may face when analyzing 67 routine data. Although routine data are not primarily collected for research purposes, their use 68 and longitudinal linkage with data from other sources such as registries or biobanks has the potential to improve health care and regulatory decision making [2,5]. However, it is not only 69 70 the linkage to other data sources that is important but also the ability to aggregate data from 71 different hospitals or even across different countries and health care systems given a common 72 data model.

Randomized controlled trials (RCTs) are the gold standard for answering questions about 73 74 treatment efficacy and safety. However, analyzing RWD may be useful to bridge evidence 75 gaps at the interface to clinical practice. Utilizing routine data offers several advantages, 76 including a large number of observations, especially when leveraging and linking multiple clinical data sources. It allows the coverage of different locations, patient populations (e.g., 77 different age distribution or disease severity), and practice patterns in routine health care 78 79 [1,3,6]. Routine data analysis can also be valuable when RCTs are not feasible due to ethical 80 or practical reasons. Particularly in the context of treatment comparisons, the use of the target 81 trial emulation framework allows to obtain comparable results to those observed in RCTs when 82 carefully and fully emulated [7–9]. An alternative approach, rather than relying solely on routine data or their linkage for treatment comparison, is to use the data as an external control [2,10]. 83


Yet, as routine data are documented for reimbursement or clinical care purposes, the quality 84 of the data from a research perspective is typically lower than that of other prospectively 85 planned studies – including RCTs. Routine data may lack harmonization and interoperability, 86 may often be incomplete and some relevant information may be missing [4]. For instance, body 87 88 mass index is generally irrelevant for reimbursement purposes but might be a potential risk factor, confounder or effect modifier for several research questions, especially in the field of 89 non-communicable diseases, such as those investigated by Zöller et al. [11] on chronic 90 91 obstructive pulmonary disease (COPD). The analysis of such data is therefore fraught with 92 methodological challenges, including confounding and several potential biases which are 93 already well-known from clinical epidemiology. Beyond these common concerns, it remains unclear which additional limitations related to routinely collected data, particularly challenges 94 at measurement level - such as how data is collected and translated into variables used for 95 96 analysis - appear frequently [12].

For structuring an investigation on limitations, we suggest three scenarios, derived from the
field of clinical epidemiology where routine data hold high potential for generating RWE: (1) *Burden of Disease*, (2) *Safety and Risk Group Analysis*, and (3) *Treatment Comparison*. *Burden of Disease* describes the impact of a disease or health problem on a specified

101 population, quantified by metrics such as incidence, prevalence, mortality, morbidity, quality of 102 life, and economic impact [13]. As this scenario typically includes the given health care setting 103 in the definition of the study population, we consider it as the most natural application of routine 104 data. Safety and Risk Group Analysis covers adverse events of various medical interventions such as treatments, medications, devices and procedures, with a potential focus on identifying 105 and characterizing subgroups with a higher risk profile in the respective population (e.g., due 106 to comorbidities, genetic predispositions, or general demographic characteristics) [14]. Here, 107 108 routine data offer the possibility of long-term observations, to study rare subgroups and adverse events, as well as to observe patients with different comorbidities, and co-109 110 medications. As this scenario is characterized by time-sensitive and potentially unobservable 111 or undocumented information, it is more complex than the Burden of Disease scenario. 112 Treatment Comparison deals with the causal effects of medical treatments. This area is and will continue to be dominated by evidence from RCTs. However, with the beginning of 2025, a 113 new EU regulation for health technology assessment will enter into force. Although the process 114 115 is still in development, health technology developers will need to address a high number of 116 PICOs with diverse comparators [15]. Combined with the tight timelines in the joint clinical assessment process, clinical studies will not be available for all PICOs, creating a high need 117 for additional data sources like routine data. In addition, routine data offer the opportunity to 118 study the effects in a routine setting, including effects of noncompliance, rare subgroups or 119 120 subgroups not typically eligible for clinical studies, confounding by indication as well as potential effects of site-specific impact factors on treatment outcome. Here, similar issues as 121 in Safety and Risk Group Analysis complicate the statistical analysis, especially due to the 122 causal interpretation of the primary outcome. 123

In this work, we aim to provide an overview of the reported challenges and biases inherent in routine data analysis with respect to their potential impact in the three main scenarios. This is accomplished in a step-wise procedure as illustrated in Figure 1. First, a systematic literature search is conducted to extract the limitations outlined in the respective discussion sections. Second, a subsequent focus group discussion with experts is held to supplement and to

- 129 evaluate the identified list of challenges. Finally, we identified challenges that have a
- 130 comparably high potential to affect the analysis findings and require thorough consideration
- 131 and discussion in order to draw meaningful conclusions.
- 132 Figure 1 Process Flow Diagram



#### 133

Overview of the process used in this work to identify and evaluate challenges and biases in routine care data analysis. This includes (1) a systematic literature search to extract reported limitations followed by (2) expert focus group discussions to supplement and discuss these challenges regarding their impact on real-world evidence.

### 138 Methods

#### 139 Data sources and search strategies

In October 2023, we conducted a systematic search of MEDLINE via PubMed. The search focused on English-language publications in the following top-ranked journals based on the Journal Citation Reports (JCR) category "Medicine, General & Internal" as of 2022 [16]: (i) The Lancet, (ii) New England Journal of Medicine, (iii) Journal of the American Medical Association (JAMA) and (iv) British Medical Journal (BMJ). In addition, we included the following oncology journals, based on our experience, as RWE is particularly prevalent in this therapeutic field [17]: (v) JAMA Oncology, (vi) The Lancet Oncology, and (vii) Journal of Clinical Oncology. In

147 order to ensure recency and thereby relevance of the articles, the search included all original 148 articles published between January 2018 and October 2023. The following terms were queried 149 in the title or abstract: "real-world evidence", "RWE", "Real-world data", "real-world", "routine 150 data", "routine care data", "Emulation" and "Electronic health data". A study was defined as being eligible if routine clinical care data collected by the healthcare system, such as 151 longitudinal claims data or EHR, was analyzed. Other types of publications, such as 152 153 comments, letters, perspectives or reviews were excluded. Studies were also excluded, in 154 which only registry data or manually collected data were analyzed. In addition, we assessed if 155 any aspect from the three pre-defined scenario categories were investigated in the studies: (1) Burden of Disease, (2) Safety and Risk Group Analysis, and (3) Treatment Comparison. If this 156 was not the case, the study was excluded. The detailed search strategy is described in the 157 158 Supplementary Material (Supplementary S1). All articles were indexed and organized using 159 Zotero.

Three reviewers (MP, KG, KU) independently screened each publication through all stages of the review process. First, titles and abstracts of the search results were screened to ensure relevance and adherence to the inclusion and exclusion criteria. In a second step, the full texts of the included abstracts were assessed to obtain a final decision on inclusion in the review. In case of any discrepancy between two reviewers regarding the eligibility of specific studies, an additional independent reviewer (MB) was consulted to resolve the issue. The review was pre-specified and registered in PROSPERO (CRD42023477616).

167

#### 168 Data extraction and categorization

Methodological challenges and limitations mentioned in the discussion sections of the included publications were extracted as the main outcome. In addition, study characteristics such as design, the underlying data sources, the country from which data was obtained, the methods employed, and the purpose of the published studies were retrieved. Publications were categorized into the three predefined main areas of application (Burden of Disease, Safety and Risk Group Analysis, Treatment Comparison), based on their research question. The extracted

175 limitations were subsequently assigned to the main bias categories in non-randomized studies as defined in the Cochrane Handbook: confounding, selection bias, information bias and 176 177 reporting bias [18]. We identified five specific categories to highlight potential biases that are 178 specific to the use of routine data. First, as clinical routine data is primarily collected for reimbursement purposes based on clinic-specific coding practices, the category Coding 179 Challenges is introduced. This category includes for example discrepancies in coding practices 180 between clinics or specificalities of the ICD10 (the International Classification of Diseases and 181 182 Related Health Problems) coding system [19]. This challenge may lead to information bias, specifically misclassification or detection bias, regardless of the already well-known detection 183 bias, which typically result from varying quality in detection methods. Second, as one of the 184 main drivers of documentation quality is again reimbursement as well as patient care rather 185 than research, the category Operationalization or Availability of Variables is established to 186 address to which extent studies were restricted by the availability of the data for answering the 187 research question. This type of missing data may lead to unmeasured confounding and 188 189 potential selection bias. Third, routine data may suffer from other types of missing data, i.e., 190 missing records in certain variables, as typically known from observational studies, resulting in the category *Missing Data*. Fourth, routine data may also suffer from different lengths of follow-191 192 up largely varying between patients, for which we introduce a further category called Followup Challenges. Finally, the category Validation & Data Quality is added, which leads to 193 194 potential bias as large amounts of routine data typically cannot be carefully validated. This also 195 includes the variability of data quality over time arising e.g., due to changes in coding systems, such as transitions between versions of the ICD coding standard, or the ongoing digitalization 196 of hospitals. 197

We did not assess the quality or risk of bias of individual studies since we were not extracting data or outcomes of the studies for subsequent analysis and we were only interested in their stated limitations. Still, we expected that there were challenges not reported in the study publications, e.g., because of limited relevance or lack of awareness. Therefore, a subsequent

focus group meeting was initiated for complementing and ranking the identified list of challenges.

#### 204 Focus Group

At a four-hour workshop, the results of the systematic literature search were presented in the 205 206 form of a slide presentation for each scenario to a selected group of co-authors of this 207 manuscript plus one independent expert from the area of health technology assessments. After 208 each scenario was presented, focus group members were asked to add potential additional 209 challenges in a moderated joint discussion. In addition, through a General category, we left 210 room for limitations and challenges that can be found in RWD studies not specific to any of the three scenarios. All identified challenges were listed for a subsequent voting on their potential 211 impact within each scenario. Every focus group member had two votes for each of the three 212 main scenarios, plus one additional vote for the General category. All challenges with at least 213 214 one vote were summarized and considered as key challenges deemed to have a high potential to influence the results requiring thorough consideration in analyses. 215


### 216 **Results**

### 217 Study selection and characteristics

218 In total, 227 records were identified from MEDLINE of which 15 duplicate publications and 1 219 audio interview were removed, leading to 211 records eligible for title and abstract screening. 220 From this first screening, we excluded 142 publications because they were not original 221 research articles, were only methods articles, or did not use routinely collected data from 222 clinical care. In a second step, 69 records were evaluated in a full-text screening for verifying the data source as coming from electronic health records or administrative data, and to be 223 224 categorizable into the three main scenarios. Finally, 39 studies were included in the review. An overview of the review process and study selection is depicted in Figure 2. 225

226

#### 228 Figure 2 PRISMA flow diagram [20]



229

A brief summary of the study characteristics is shown in Table 1. Most of the studies were 230 published in BMJ (36%), with 55% being published in the past two years (2022 and 2023). This 231 is supporting our decision to limit the search to the past five years. The majority of extracted 232 233 publications (46%) was based on data from the US. While some publications used only EHR data (59%), other studies linked this information to additional sources, such as biobanks or 234 registries (28%). The use of data sources varied between studies, from single-country to 235 multinational studies. The majority of the publications used nation-wide (46%) or multi-center 236 237 data (38%), while the remaining studies used multi-national (10%), single-center (3%) and 238 territory-wide (3%) data.

| Study Characteristics        | n (%)     |
|------------------------------|-----------|
| Journals                     |           |
| BMJ                          | 14 (35.9) |
| JAMA                         | 9 (23.1)  |
| New England Journal of       | 4 (10.2)  |
| Medicine                     | . ()      |
|                              | 5 (12.8)  |
| The Lancet                   |           |
| JAMA Oncology                | 2 (5.1)   |
| Journal of Clinical Oncology | 5 (12.8)  |
| Year                         |           |
| 2018                         | 1 (2.6)   |
| 2019                         | 5 (12.8)  |
| 2020                         | 4 (10.3)  |
| 2021                         | 7 (18.0)  |
| 2022                         | 10 (25.6) |
| 2023                         | 12 (30.8) |
| Country                      |           |
| Canada                       | 1 (2.6)   |
| France                       | 1 (2.6)   |
| Hong Kong                    | 1 (2.6)   |
| Israel                       | 3 (7.7)   |
| South Korea                  | 1 (2.6)   |
| UK                           | 5 (12.8)  |
| UK + Canada                  | 1 (2.6)   |
| UK + USA                     | 2 (5.1)   |
| USA                          | 18 (46.2) |
| USA + South Korea            | 1 (2.6)   |
| Qatar                        | 1 (2.6)   |
| >2 countries                 | 4 (10.2)  |
| Data Source                  |           |
| EHR                          | 23 (59.0) |
| EHR + additional linked      | 11 (28.2) |
| data*                        |           |
| Administrative data**        | 5 (12.8)  |
| Scope of Data                |           |
| single-center                | 1 (2.6)   |
| multi-center                 | 15 (38.5) |
| territory-wide               | 1 (2.6)   |
| nation-wide                  | 18 (46.2) |
| multi-national               | 4 (10.3)  |

240 In this table, the number of studies *n*, along with its percentage in brackets (%), is presented for

241 each category. EHR= Electronic health records

\* additional linked data include exome sequencing data, hospital admission data, mortality data, 242

243 data from biobanks, claims data, questionnaire data, and data from registries

244 \*\* administrative data include insurance information and claims data

246 Figure 3 provides a summary of the limitations mentioned in the discussion section of the extracted studies stratified into the data source types and according to their assigned scenario 247 248 category. In total, there are 11 publications in the category Burden of Disease, 17 publications 249 in Safety and Risk Group Analysis and 11 publications in Treatment Comparison. As expected, the main bias types are typically mentioned in the publications. However, it is important to 250 recognize the additional biases that frequently appear. A detailed overview for each publication 251 is provided in the Supplementary Material S2 – Table S3, including a broad overview of the 252 253 study design including the main outcomes and their respective methods, objectives, and the 254 scope of the analysis in terms of data use.

|                         |             | Main Bias Categ | gories         |                     | Additional Bias | Categories           |   |              |                         |                             |
|-------------------------|-------------|-----------------|----------------|---------------------|-----------------|----------------------|---|--------------|-------------------------|-----------------------------|
|                         |             | Confounding     | Selection Bias | Information<br>Bias | Reporting Bias  | Coding<br>Challenges | Operationalizat<br>ion or<br>Availability of<br>Variables | Missing Data | Follow-up<br>Challenges | Validation &<br>Data Qualit |
| *                       | EHR         | 3               | 4              | 5                   | 2               | 2                    | 2   | 3            |                         |                             |
| Burden of<br>Disease    | Linked EHR  | 2               | 3              | 2                   | 1               |                      |   | 1            | 2                       | 2                           |
| Burd<br>Dise            | Admin. Data | _               | 1              |                     |                 |                      |   |              |                         |                             |
| đ                       | EHR         | 7               | 4              | 5                   | 2               |                      | 3   | 2            | 3                       | 2                           |
| fy &<br>Gro             | Linked EHR  | 4               | 4              | 6                   | 4               | 2                    | 1   | 2            |                         | 2                           |
| Safety &<br>Risk Group  | Admin. Data | 2               | 2              | 2                   | 1               |                      | 2   | 1            | 2                       |                             |
|                         | EHR         | 9               | 9              | 7                   |                 | 1                    | 3   | 2            |                         | 1                           |
| Treatment<br>Comparison | Linked EHR  | _               |                |                     |                 |                      |   |              |                         |                             |
| Com                     | Admin. Data | 2               | 2              | 1                   |                 |                      |   |              | 1                       |                             |


#### 255 Figure 3 Summary of biases extracted from the studies

256

Number of studies facing the main biases and additional identified bias categories grouped
by data source types and the main scenarios: *Burden of Disease, Safety and Risk Group Analysis, and Treatment Comparison.* Abbreviations: EHR...Electronic Health Records, Admin. Data...
Administrative Data

In the following, we summarize the findings on methodological challenges and limitations from
both the review and the focus group workshop for each main scenario, separately. In Figure
4, all challenges that were added and ranked according to their relevance in the focus group
discussion are summarized.

#### 265 Figure 4 Overview of Workshop Results



Findings of the focus group discussion divided into the three main scenarios: *Burden of Disease, Safety and Risk Group Analysis*, and *Treatment Comparison*, as well as the additional category *General Limitations*. The content stated within the blue colored areas are the voting result, with the plus signs (+) indicating the importance weighting. The blue font highlights challenges and limitations already occurring in the systematic search. The black font and particularly the content outside the blue area are limitations and challenges added by the focus group.

#### 273 Burden of disease

Five publications reported limitations potentially leading to confounding. Of these, two studies 274 had limited availability of variables included in the analysis resulting in the possibility of 275 276 unmeasured confounding [21,22]. However, Kamran et al. [22] argued that with the use of a 277 limited number of variables in the model a reliable identification and validation of all variables 278 even across different institutions was feasible. Limitations related to the risk of selection bias 279 were present in eight studies. On the one hand, in Canavan et al. [21] a volunteer bias could 280 not be ruled out because the data used for the analyses included individuals who opted to be included in the study database. On the other hand, in Witberg et al. [23] the absence of 281 simultaneously enrolled comparison groups was mentioned which could lead to a potential 282 selection bias. Moreover, some studies highlighted the fact that the results might not be 283 284 transferable to other clinical practices or populations [21,24-26]. The primary type of information bias (n=7) observed was misclassification bias, affecting either the exposure or 285 outcome [21,24,27,28]. Beck et al. [24] highlighted that clinical diagnoses were probably not 286 287 fully captured due to challenges in diagnostic and physician coding. On the other hand, Manz 288 et al. [28] noted a limitation indicating that they were limited to use only patients with a coded classifier variable for comparing the machine learning model with the commonly used 289 prognostic reference. This limitation resulted from differences in the characteristics of the 290 291 patients with and without the coded variable. Kamran et al. [22] additionally emphasized that 292 even though a common EHR provider across facilities was implemented, it remains crucial to 293 have in-depth knowledge of the local deployment. Two studies reported limited follow-up time 294 [26,29]. However, Biccler et al. [29] noted that despite the longer follow-up period compared

to clinical trials, it was still insufficient to evaluate very long-term effects. The lack of health record validation was reported in two studies [29,30]. While all studies acknowledged limitations in their discussions, only three studies [22,25,27] took an additional step to assess these limitations in the context of their specific study.

During the focus group discussion, further limitations were added to those identified in the 299 literature review and are presented in the first part of Figure 4. Some relevant and reasonable 300 301 limitations added by the experts were the inconsistency of the data quality over time. This 302 challenge is interconnected to the adjustment or calibration of algorithms to dynamic data 303 changes, especially when using a model that continuously uses recent data from routine clinical care. Additionally, the heterogeneity and specialization of hospitals substantially impact 304 the burden of disease. Including only hospitals with specializations in a certain disease 305 treatment would overestimate the burden. Another added limitation was missing information 306 due to death in situations with death as competing risk, where it would be impossible to 307 308 diagnose the disease even though the patient may have had it [31].

The rating of the limitations of *Burden of Disease* is indicated by the blue area in Figure 4. The 309 transferability of study results to a larger population, which goes hand in hand with the 310 possibilities of selection bias, missing data and misclassification of data, was weighted by the 311 experts to be most important. The importance of data quality in EHR data was also recognized, 312 specifically the variability of data quality over time due to e.g., changes in coding systems, 313 such as transitions between versions of the ICD coding standard, or individual coding behavior. 314 315 This could potentially introduce bias to the results concerning the burden of a disease, particularly when comparing diagnoses from the present to the past or the burden over an 316 extended period of time. 317

### 318 Safety and Risk Group Analysis

In this category, the information bias was predominantly manifested as the risk for misclassification bias [32–40] with only one study addressing immortal time bias [38]. Specifically, certain limitations were connected with coding challenges, since the classification

was based on diagnosis codes from the EHR systems [33,35]. In addition, some form of 322 potential information bias occurred because the drug use in an EHR system had been defined 323 324 as the prescription of the medication and not as the actual drug intake [36,41]. Aspects like the 325 quantification and analysis of information concerning the physician's decision-making process for treatment selection, treatment switching or the effect of pre-treatment were often missing 326 or inadequately explored [38,40,42] which could lead to confounded results. Details regarding 327 328 adherence or dosage, as well as unstructured free-text information, were not accessible 329 [40,42,43]. Additionally, significant risk factors, such as smoking, were not available, creating a potentially high risk of confounding in the analysis. Selection bias limitations were evident in 330 331 ten studies including volunteer bias due to the involvement of individuals who volunteered to join the database used for analysis [35,44]. Moreover, several studies highlighted site 332 333 heterogeneity, noting that certain hospitals with robust programs may have had a higher burden of disease [33-35]. The limitation of missing data was mentioned in five studies 334 [33,36,38,39,45], for instance, in Li et al. [36] who stated that EHR data sources lacked 335 336 comprehensive coverage of medical events recorded in other healthcare facilities. While only 337 three studies [38,43,44] explicitly stated their limitations without providing further elaboration. the remaining studies either addressed how they mitigated certain limitations through selected 338 methodologies or sensitivity analyses [34,36,37,39-42,45,46]. Alternatively, they presented 339 arguments explaining why certain limitations were unlikely or invalid in the context of their 340 341 specific study [32,33,35,39,45,47].

A few specific challenges were added by the experts in the focus group discussion as displayed in the second section of Figure 4. First, it is considered important to correctly distinguish between the case and patient definition. Given that patients may have multiple cases associated with them in routine clinical data, it is essential for the research question to specify whether the data refers to the patient level or the individual case level. The lack of clarity could potentially violate the i.i.d-assumptions (independent and identically distributed assumption), which is the basis for many commonly used statistical methods.

Second, another challenge mentioned is the problem of reverse p-hacking for safety endpoints, where the analysis is manipulated to intentionally favor non-significant results [48]. Third, the focus group emphasized the importance of the limitation related to the lack of follow-up data, especially in health care systems where no linkage with routine outcome information is available. A longer follow-up period is crucial for conducting thorough safety analyses to observe adverse events. This aspect is closely linked to the issue of missing information due to death, as death prevents the observation of subsequent adverse events.

Moreover, the experts added several limitations related to medication use. These included insufficient information on the reasons for change in medication and its effect, as well as information on dosage. Additionally, concerns were raised about the off-label use of medication. Unlike in controlled clinical trials, the treatment paths of patients are quite heterogeneous due to the decisions of the clinician or the different specializations of the hospitals.

#### 362 Treatment Comparison

363 Confounding remained a particular area of concern, specifically in achieving balance between 364 the groups. Kim et al. [49] reported persistent imbalance in variables even after applying matching techniques. However, they addressed this issue by adjusting for these variables in 365 366 further analyses. Likewise, Xie et al. [50] stated that individuals treated with the study medication had a higher baseline health burden, potentially leading to underestimated findings 367 due to residual confounding. Only two studies explicitly report missing risk factors that could 368 subsequently not be used for balancing [51,52]. Wang et al. [8] highlighted that claims data 369 had not recorded medication use in hospital, therefore, they needed to use alternative index 370 date and follow-up definition. Similar to the Safety and Risk Group Analysis, most potential 371 information biases were a type of misclassification [50,53–56]. Rentsch et al. [52] reported that 372 373 the identification of outcome events was not provided by a validated algorithm, which could also potentially lead to information bias. Same holds true for Wong et al. [57] as they did not 374 distinguish the reason for deaths. Kim et al. [49] emphasized the general issues of immortal 375

time and time lag biases in the discussion section, but elaborated on the methods used to 376 address and avoid these biases. One study noted the concern of potential upcoding, i.e. the 377 intentional use of ICD-10 and OPS (Operation and Procedure Classification System) codes 378 379 with the greatest reimbursement rather than those with the greatest clinical relevance, resulting in overstating the patient's severity of disease [58]. Xie et al. [55] highlighted that the 380 381 effectiveness of the investigated drug could be overestimated in individuals with poor health characteristics who opt not to receive treatment, while those with better health characteristics 382 who decide not to be treated could lead to underestimation. The studies predominantly stated 383 their open limitations including those that persisted despite implementing causal inference 384 385 methods or conducting sensitivity analyses aimed at addressing them [50,52,53,55]. Beyond that, Kim et al. [49] detailed how they mitigated their limitations. 386

The focus group discussion resulted in the following additions. First, data availability with 387 regard to the transferability within different health care sectors, e.g., ambulatory and stationary 388 sector, was added as challenge, especially for Germany [59]. Second, the timing of an 389 390 intervention is also critical to assess its effectiveness accurately, understand its impact on patient outcomes, and make informed clinical decisions. In EHR or administrative databases, 391 the timing may not be explicitly recorded or may be subject to errors or omissions. Third, the 392 difficulty in defining control groups for comparison was highlighted as well as the verifiability of 393 the inclusion or exclusion criteria [9,60]. Fourth, similar to the Safety and Risk Group Analysis 394 scenario, follow-up duration is critical. However, in the context of treatment comparison, the 395 criticality arises also from the possibility that drugs can have a longer delay in efficacy. 396

Compared to the previous scenarios the ratings of the *Treatment Comparison* category were more widely distributed, with votes spread across numerous limitations. This distribution highlighted the wide range of challenges to consider. Residual confounding and immortal time bias received the majority of votes. Not only the data availability of different data sectors, but also the availability of variables was considered important which is connected to residual confounding, e.g. absence of known confounders.

### 403 General limitations and challenges

The focus group viewed the linkage of records, the validation of data and the selection of measurements as critical to conduct routine care data analysis. If there are multiple measurements, it can be challenging to specify which measurement is considered as the relevant one. In connection with record-linkage, both with other hospitals and other data sources, the cases and patient data may overlap between hospitals and other data sources. In addition, the challenges with the definition of estimands and estimators was highlighted [14,61,62].

### 411 Discussion

#### 412 Major findings of this work briefly summarized

This review aimed to present a comprehensive overview of the limitations and biases inherent in the analysis of routine clinical care data. Additionally, we pinpointed the challenges with the greatest potential to influence the results of the analysis emphasizing thorough consideration and discussion for the derivation of meaningful inference. We have intentionally provided a comprehensive overview of the study's features to serve as a guide, categorically organized into different scenarios.

#### 419 Strength and limitations of this work

420 Particular strengths of this work are, first, the inclusion of high impact journals in the review to 421 focus on the databases with highest potential for routine data analyses and use of a broad search strategy to cover the work analyzing data routinely collected within the healthcare 422 system. Second, we extracted and categorized the limitations and potential biases identified 423 424 in the publications. In addition, our two-step procedure, which included a subsequent focus 425 group evaluation, resulted in a more comprehensive overview of potential challenges. Finally, this review only included studies that were successfully published. Therefore, we could not 426 identify challenges that prevented successful data analyses and publication. 427

Naturally, this study is also subject to further limitations. Firstly, by restricting our search 428 strategy to high-impact publications for the sake of recency and relevance, there is a possibility 429 430 that we overlooked certain publications and their associated limitations. However, the 431 incorporation of expert experiences and knowledge helped to cover any missed challenge. Second, given that our panel consisted solely of German experts in the field of statistics and 432 clinical epidemiology, the added limitations might be influenced by local challenges specific to 433 434 this context and might miss the important aspects such as the international or the clinical perspective. 435

Our study assessed various limitations faced across different study scenarios of interest, 436 resulting in a ranked list of potentially relevant challenges. While our focus was specifically on 437 limitations stated in the discussion section of publications, we did not provide explicit methods 438 439 to address these limitations. However, this has already been partially discussed in other works 440 [10,63]. The choice of the applied methods of causal inferences, such as propensity score techniques or the method of target trial emulation for established treatments, serves to reduce 441 potential biases and preventing fundamental errors in the study design. In the next step, we 442 443 aim to explore the requirements and concerns of various stakeholders regarding the use of routine clinical data to achieve different objectives, particularly in therapeutic evaluations. This 444 will involve understanding the diverse expectations, needs, and potential challenges faced by 445 stakeholders in leveraging routine clinical data for meaningful and accurate therapeutic 446 447 assessments.

### 448 Conclusion

This review provides a comprehensive examination of potential limitations and biases in analyses of routine clinical care data reported in recent high-impact journals. We highlighted challenges that could significantly influence analysis results, stressing the necessity for thorough consideration and discussion to derive meaningful conclusions.

453

| 454 | Abbreviations | Chronic Obstructive Pulmonary Disease                                |
|-----|---------------|--|
|     | EHR           | Electronic Health Records  |
|     | ICD           | International Classification of Diseases and Related Health Problems |
|     | JCR           | Journal Citation Report  |
|     | OPS           | Operation and Procedure Classification<br>System                     |
|     | RCT           | Randomized Controlled Trial  |
|     | RWD           | Real-World Data  |
|     | RWE           | Real-World Evidence  |
|     |               |  |

- 455 Ethics approval and consent to participate
- 456 Not applicable

## 457 Consent for publication

- 458 Not applicable
- 459 Availability of data and materials
- 460 Not applicable

### 461 Competing interests

462 The authors declare that they have no competing interests.

# 463 Funding

This work was funded by the Federal Ministry of Education and Research (BMBF) in Germany in the framework of the EVA4MII project (FKZ 01ZZ2308A, 01ZZ2308B, 01ZZ2308C). The funding agency had no role in the design, data collection, analyses, interpretation, and reporting of the study. The work of HB, MB, and NB has also been funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – Project-ID 499552394 – SFB 1597.

# 470 Authors' contributions

MP, DZ, HB and NB developed the study conception and design. MP, MB, KU and KG were involved in the systematic search process. MP extracted the data from the publications. KU and KG critically reviewed the extraction. MP wrote the first draft of the manuscript; NB supervised this process. MB, DZ, HB, VR, JRP, PH, MK, FR and AS provided additional intellectual content to the manuscript. All authors critically reviewed and approved the final version.

## 477 Acknowledgments

478 We would like to thank the participants of the focus group workshop for the joint discussion.

479

### 480 **References**

481 [1] Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, et al. Real482 World Evidence — What Is It and What Can It Tell Us? N Engl J Med 2016;375:2293–7.
483 https://doi.org/10.1056/NEJMsb1609216.

Rahman R, Ventz S, McDunn J, Louv B, Reyes-Rivera I, Polley M-YC, et al.
Leveraging external data in the design and analysis of clinical trials in neuro-oncology.
Lancet Oncol 2021;22:e456–65. https://doi.org/10.1016/S1470-2045(21)00488-5.

487 [3] Franklin JM, Schneeweiss S. When and How Can Real World Data Analyses
488 Substitute for Randomized Controlled Trials? Clin Pharmacol Ther 2017;102:924–33.
489 https://doi.org/10.1002/cpt.857.

490 [4] Liu F, Panagiotakos D. Real-world data: a brief review of the methods, applications,
491 challenges and opportunities. BMC Med Res Methodol 2022;22:287.
492 https://doi.org/10.1186/s12874-022-01768-6.

493 [5] Cowie MR, Blomster JI, Curtis LH, Duclaux S, Ford I, Fritz F, et al. Electronic health
494 records to facilitate clinical research. Clin Res Cardiol 2017;106:1–9.
495 https://doi.org/10.1007/s00392-016-1025-6.

496 [6] Sheldrick RC. Randomized Trials vs Real-world Evidence: How Can Both Inform
497 Decision-making? JAMA 2023;329:1352–3. https://doi.org/10.1001/jama.2023.4855.

498 [7] Hernán MA, Wang W, Leaf DE. Target Trial Emulation: A Framework for Causal
499 Inference From Observational Data. JAMA 2022;328:2446.
500 https://doi.org/10.1001/jama.2022.21383.

[8] Wang SV, Schneeweiss S, Franklin JM, Desai RJ, Feldman W, Garry EM, et al.
Emulation of Randomized Clinical Trials With Nonrandomized Database Analyses: Results of
32 Clinical Trials. JAMA 2023;329:1376–85. https://doi.org/10.1001/jama.2023.4221.

504 [9] Hernán MA, Robins JM. Using Big Data to Emulate a Target Trial When a

Randomized Trial Is Not Available: Table 1. Am J Epidemiol 2016;183:758–64.
https://doi.org/10.1093/aje/kwv254.

507 [10] Burger HU, Gerlinger C, Harbron C, Koch A, Posch M, Rochon J, et al. The use of
508 external controls: To what extent can it currently be recommended? Pharm Stat
509 2021;20:1002–16. https://doi.org/10.1002/pst.2120.

510 [11] Zöller D, Haverkamp C, Makoudjou A, Sofack G, Kiefer S, Gebele D, et al. Alpha-1-511 antitrypsin-deficiency is associated with lower cardiovascular risk: an approach based on 512 federated learning. Respir Res 2024;25:38. https://doi.org/10.1186/s12931-023-02607-y.

- 513 [12] Schneeweiss S. Von Real-World-Daten zur Real-World-Evidenz: eine praktische
   514 Anleitung. Prävent Gesundheitsförderung 2023. https://doi.org/10.1007/s11553-023-01026-7.
- [13] Hessel F. Burden of DiseaseBurdenof disease(s). In: Kirch W, editor. Encycl. Public
  Health, Dordrecht: Springer Netherlands; 2008, p. 94–6. https://doi.org/10.1007/978-1-40205614-7\_297.
- 518 [14] Unkel S, Amiri M, Benda N, Beyersmann J, Knoerzer D, Kupas K, et al. On
- 519 estimands and the analysis of adverse events in the presence of varying follow-up times
- 520 within the benefit assessment of therapies. Pharm Stat 2019;18:166–83.
- 521 https://doi.org/10.1002/pst.1915.
- 522 [15] Buchholz I. PT28 Lost in PICO? a Simulation of the EU HTA Scoping Process n.d.
- 523 [16] 2022 Journal Impact Factor, Journal Citation Reports (Clarivate, 2023) n.d.
- 524 [17] Purpura CA, Garry EM, Honig N, Case A, Rassen JA. The Role of Real-World
  525 Evidence in FDA-Approved New Drug and Biologics License Applications. Clin Pharmacol
  526 Ther 2022;111:135–44. https://doi.org/10.1002/cpt.2474.
- 527 [18] Sterne JAC, Hernán MA, McAleenan A, Reeves BC, Higgins JPT. Chapter 25:
  528 Assessing risk of bias in a non-randomized study. In: Higgins JPT, Thomas J, Chandler J,
  529 Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic
  530 Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023. Available from
  531 : www.training.cochrane.org/handbook.
- [19] World Health Organization. ICD-10: international statistical classification of diseases
  and related health problems: tenth revision, 2nd ed. World Health Organization. 2004.
  https://iris.who.int/handle/10665/42980.
- [20] Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The
  PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev
  2021;10:89. https://doi.org/10.1186/s13643-021-01626-4.
- [21] Canavan M, Wang X, Ascha M, Miksad R, Showalter TN, Calip G, et al. End-of-Life
  Systemic Oncologic Treatment in the Immunotherapy Era: The Role of Race, Insurance, and
  Practice Setting. J Clin Oncol Off J Am Soc Clin Oncol 2023;41:4729–38.
  https://doi.org/10.1200/JCO.22.02180.
- 542 [22] Kamran F, Tang S, Otles E, McEvoy DS, Saleh SN, Gong J, et al. Early identification
  543 of patients admitted to hospital for covid-19 at risk of clinical deterioration: model
  544 development and multisite external validation study. BMJ 2022;376:e068576.
  545 https://doi.org/10.1136/bmj-2021-068576.
- 546 [23] Witberg G, Barda N, Hoss S, Richter I, Wiessman M, Aviv Y, et al. Myocarditis after
  547 Covid-19 Vaccination in a Large Health Care Organization. N Engl J Med 2021;385:2132–9.
  548 https://doi.org/10.1056/NEJMoa2110737.

medRxiv preprint doi: https://doi.org/10.1101/2024.09.05.24313049; this version posted September 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

[24] Beck DB, Bodian DL, Shah V, Mirshahi UL, Kim J, Ding Y, et al. Estimated 549 Prevalence and Clinical Manifestations of UBA1 Variants Associated With VEXAS Syndrome 550 in a Clinical Population. JAMA 2023;329:318-24. https://doi.org/10.1001/jama.2022.24836. 551

Forrest IS, Petrazzini BO, Duffy Á, Park JK, Marquez-Luna C, Jordan DM, et al. 552 [25] Machine learning-based marker for coronary artery disease: derivation and validation in two 553 554 longitudinal cohorts. Lancet Lond Engl 2023;401:215-25. https://doi.org/10.1016/S0140-6736(22)02079-7. 555

Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, et al. Interim findings 556 [26] 557 from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet Lond Engl 2021;397:1646-57. 558 https://doi.org/10.1016/S0140-6736(21)00677-2. 559

560 [27] Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 561 562 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an 563 observational study using national surveillance data. Lancet Lond Engl 2021;397:1819-29. https://doi.org/10.1016/S0140-6736(21)00947-8. 564

[28] Manz CR, Chen J, Liu M, Chivers C, Regli SH, Braun J, et al. Validation of a Machine 565 Learning Algorithm to Predict 180-Day Mortality for Outpatients With Cancer. JAMA Oncol 566 2020;6:1723-30. https://doi.org/10.1001/jamaoncol.2020.4331. 567

Biccler JL, Glimelius I, Eloranta S, Smeland KB, Brown P de N, Jakobsen LH, et al. 568 [29] Relapse Risk and Loss of Lifetime After Modern Combined Modality Treatment of Young 569 Patients With Hodgkin Lymphoma: A Nordic Lymphoma Epidemiology Group Study. J Clin 570 Oncol Off J Am Soc Clin Oncol 2019;37:703–13. https://doi.org/10.1200/JCO.18.01652. 571

Chang AR, Moore BS, Luo JZ, Sartori G, Fang B, Jacobs S, et al. Exome Sequencing 572 [30] 573 of a Clinical Population for Autosomal Dominant Polycystic Kidney Disease. JAMA 2022;328:2412-21. https://doi.org/10.1001/jama.2022.22847. 574

Binder N, Blümle A, Balmford J, Motschall E, Oeller P, Schumacher M. Cohort 575 [31] 576 studies were found to be frequently biased by missing disease information due to death. J Clin Epidemiol 2019;105:68–79. https://doi.org/10.1016/j.jclinepi.2018.09.010. 577

Cohen-Stavi CJ, Magen O, Barda N, Yaron S, Peretz A, Netzer D, et al. BNT162b2 578 [32] 579 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age. N Engl J Med 2022;387:227-36. https://doi.org/10.1056/NEJMoa2205011. 580

Damrauer SM. Chaudharv K. Cho JH. Liang LW. Argulian E. Chan L. et al. 581 [33] 582 Association of the V122I Hereditary Transthyretin Amyloidosis Genetic Variant With Heart Failure Among Individuals of African or Hispanic/Latino Ancestry. JAMA 2019;322:2191–202. 583 https://doi.org/10.1001/jama.2019.17935. 584

Filion KB, Lix LM, Yu OH, Dell'Aniello S, Douros A, Shah BR, et al. Sodium glucose 585 [34] 586 cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study. BMJ 2020;370:m3342. https://doi.org/10.1136/bmj.m3342. 587

588 [35] Forrest IS, Chaudhary K, Vy HMT, Petrazzini BO, Bafna S, Jordan DM, et al. Population-Based Penetrance of Deleterious Clinical Variants. JAMA 2022;327:350-9. 589 https://doi.org/10.1001/jama.2021.23686. 590

[36] 591 Li X, Ostropolets A, Makadia R, Shoaibi A, Rao G, Sena AG, et al. Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in 592 593 eight countries: multinational network cohort study. BMJ 2021;373:n1435.

### 594 https://doi.org/10.1136/bmj.n1435.

Lyu H, Zhao SS, Zhang L, Wei J, Li X, Li H, et al. Denosumab and incidence of type 2
diabetes among adults with osteoporosis: population based cohort study. BMJ
2023;381:e073435. https://doi.org/10.1136/bmj-2022-073435.

[38] Martin P, Cohen JB, Wang M, Kumar A, Hill B, Villa D, et al. Treatment Outcomes
and Roles of Transplantation and Maintenance Rituximab in Patients With Previously
Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts. J Clin Oncol Off
J Am Soc Clin Oncol 2023;41:541–54. https://doi.org/10.1200/JCO.21.02698.

[39] Seymour CW, Kennedy JN, Wang S, Chang C-CH, Elliott CF, Xu Z, et al. Derivation,
Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis.
JAMA 2019;321:2003–17. https://doi.org/10.1001/jama.2019.5791.

[40] You SC, Rho Y, Bikdeli B, Kim J, Siapos A, Weaver J, et al. Association of Ticagrelor
vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome
Undergoing Percutaneous Coronary Intervention. JAMA 2020;324:1640–50.
https://doi.org/10.1001/jama.2020.16167.

609 [41] Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen R, Pratt N, et al.

Comprehensive comparative effectiveness and safety of first-line antihypertensive drug
classes: a systematic, multinational, large-scale analysis. Lancet Lond Engl 2019;394:1816–
26. https://doi.org/10.1016/S0140-6736(19)32317-7.

[42] Vinogradova Y, Coupland C, Hill T, Hippisley-Cox J. Risks and benefits of direct oral
anticoagulants versus warfarin in a real world setting: cohort study in primary care. BMJ
2018;362:k2505. https://doi.org/10.1136/bmj.k2505.

[43] Chavez-MacGregor M, Lei X, Zhao H, Scheet P, Giordano SH. Evaluation of COVID19 Mortality and Adverse Outcomes in US Patients With or Without Cancer. JAMA Oncol
2022;8:69–78. https://doi.org/10.1001/jamaoncol.2021.5148.

619 [44] Berry ASF, Finucane BM, Myers SM, Abril A, Kirchner HL, Ledbetter DH, et al.

620 Association of Supernumerary Sex Chromosome Aneuploidies With Venous

621 Thromboembolism. JAMA 2023;329:235–43. https://doi.org/10.1001/jama.2022.23897.

[45] Deng Y, Polley EC, Wallach JD, Dhruva SS, Herrin J, Quinto K, et al. Emulating the
GRADE trial using real world data: retrospective comparative effectiveness study. BMJ
2022;379:e070717. https://doi.org/10.1136/bmj-2022-070717.

[46] Chemaitelly H, AlMukdad S, Ayoub HH, Altarawneh HN, Coyle P, Tang P, et al.
Covid-19 Vaccine Protection among Children and Adolescents in Qatar. N Engl J Med
2022;387:1865–76. https://doi.org/10.1056/NEJMoa2210058.

- 628 [47] Harstad E, Shults J, Barbaresi W, Bax A, Cacia J, Deavenport-Saman A, et al. α2-
- 629 Adrenergic Agonists or Stimulants for Preschool-Age Children With Attention-
- 630 Deficit/Hyperactivity Disorder. JAMA 2021;325:2067–75.
- 631 https://doi.org/10.1001/jama.2021.6118.

[48] Chuard PJC, Vrtílek M, Head ML, Jennions MD. Evidence that nonsignificant results
are sometimes preferred: Reverse P-hacking or selective reporting? PLOS Biol
2019;17:e3000127. https://doi.org/10.1371/journal.pbio.3000127.

[49] Kim NH, Han KH, Choi J, Lee J, Kim SG. Use of fenofibrate on cardiovascular
outcomes in statin users with metabolic syndrome: propensity matched cohort study. BMJ
2019;366:I5125. https://doi.org/10.1136/bmj.I5125.

perpetuity. It is made available under a CC-BY 4.0 International license .

Kie Y, Bowe B, Al-Aly Z. Molnupiravir and risk of hospital admission or death in adults
with covid-19: emulation of a randomized target trial using electronic health records. BMJ
2023;380:e072705. https://doi.org/10.1136/bmj-2022-072705.

[51] Mahévas M, Tran V-T, Roumier M, Chabrol A, Paule R, Guillaud C, et al. Clinical
efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen:
observational comparative study using routine care data. BMJ 2020;369:m1844.
https://doi.org/10.1136/bmj.m1844.

[52] Rentsch CT, Beckman JA, Tomlinson L, Gellad WF, Alcorn C, Kidwai-Khan F, et al.
Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019
mortality in patients admitted to hospital in the United States: cohort study. BMJ
2021;372:n311. https://doi.org/10.1136/bmj.n311.

[53] Andersson NW, Thiesson EM, Baum U, Pihlström N, Starrfelt J, Faksová K, et al.
Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among
adults aged ≥50 years in Nordic countries: nationwide cohort study. BMJ 2023;382:e075286.
https://doi.org/10.1136/bmj-2022-075286.

[54] Deputy NP, Deckert J, Chard AN, Sandberg N, Moulia DL, Barkley E, et al. Vaccine
Effectiveness of JYNNEOS against Mpox Disease in the United States. N Engl J Med
2023;388:2434–43. https://doi.org/10.1056/NEJMoa2215201.

[55] Xie Y, Bowe B, Al-Aly Z. Nirmatrelvir and risk of hospital admission or death in adults
with covid-19: emulation of a randomized target trial using electronic health records. BMJ
2023;381:e073312. https://doi.org/10.1136/bmj-2022-073312.

[56] Zheng B, Green ACA, Tazare J, Curtis HJ, Fisher L, Nab L, et al. Comparative
effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in
patients in the community: observational cohort study with the OpenSAFELY platform. BMJ
2022;379:e071932. https://doi.org/10.1136/bmj-2022-071932.

[57] Wong CKH, Au ICH, Lau KTK, Lau EHY, Cowling BJ, Leung GM. Real-world
effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation,
and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed
SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.
Lancet Lond Engl 2022;400:1213–22. https://doi.org/10.1016/S0140-6736(22)01586-0.

[58] Marafino BJ, Escobar GJ, Baiocchi MT, Liu VX, Plimier CC, Schuler A. Evaluation of
 an intervention targeted with predictive analytics to prevent readmissions in an integrated
 health system: observational study. BMJ 2021;374:n1747. https://doi.org/10.1136/bmj.n1747.

[59] Lang C, Gottschall M, Sauer M, Köberlein-Neu J, Bergmann A, Voigt K. "Da kann
man sich ja totklingeln, geht ja keiner ran" – Schnittstellenprobleme zwischen stationärer,
hausärztlicher und ambulant-fachspezialisierter Patientenversorgung aus Sicht Dresdner
Hausärzte. Gesundheitswesen 2019;81:822–30. https://doi.org/10.1055/a-0664-0470.

- [60] D'Arcy M, Stürmer T, Lund JL. The importance and implications of comparator
  selection in pharmacoepidemiologic research. Curr Epidemiol Rep 2018;5:272–83.
  https://doi.org/10.1007/s40471-018-0155-y.
- 678 [61] Luijken K, van Eekelen R, Gardarsdottir H, Groenwold RHH, van Geloven N. Tell me 679 what you want, what you really really want: Estimands in observational
- pharmacoepidemiologic comparative effectiveness and safety studies. Pharmacoepidemiol
   Drug Saf 2023;32:863–72. https://doi.org/10.1002/pds.5620.
- 682 [62] European Medicines Agency. ICH E9 (R1) addendum on estimands and sensitivity

perpetuity. It is made available under a CC-BY 4.0 International license .

analysis in clinical trials to the guideline on statistical principles for clinical trials 2020. 683

[63] 684 Nguyen VT, Engleton M, Davison M, Ravaud P, Porcher R, Boutron I. Risk of bias in observational studies using routinely collected data of comparative effectiveness research: a 685 meta-research study. BMC Med 2021;19:279. https://doi.org/10.1186/s12916-021-02151-w. 686

Coltin H, Pequeno P, Liu N, Tsang DS, Gupta S, Taylor MD, et al. The Burden of 687 [64] Surviving Childhood Medulloblastoma: A Population-Based, Matched Cohort Study in 688 Ontario, Canada. J Clin Oncol Off J Am Soc Clin Oncol 2023;41:2372-81. 689

https://doi.org/10.1200/JCO.22.02466. 690

691 [65] Song Q, Bates B, Shao YR, Hsu F-C, Liu F, Madhira V, et al. Risk and Outcome of Breakthrough COVID-19 Infections in Vaccinated Patients With Cancer: Real-World 692 Evidence From the National COVID Cohort Collaborative. J Clin Oncol Off J Am Soc Clin 693 694 Oncol 2022;40:1414-27. https://doi.org/10.1200/JCO.21.02419.

695

#### **Supplementary Material** 696

#### Supplementary S1 697

698 Table S1 Search strategy

| (1) In Title and<br>Abstract |     | (2) Journals                           | (3) Time    |
|------------------------------|-----|--|-------------|
| real-world evidence          |     | The New England journal of medicine    |             |
| OR                           |     | OR                                     |             |
| Real-world data <b>OR</b>    |     | The Lancet. Oncology <b>OR</b>         |             |
| real-world <b>OR</b>         |     | BMJ (Clinical research ed.) <b>OR</b>  |             |
| RWE <b>OR</b>                |     | JAMA <b>OR</b>                         | Filter:     |
| routine data <b>OR</b>       | AND | Journal of clinical oncology: official | 2018 – 2023 |
|                              |     | journal of the American Society of     |             |
| routing care data OR         |     | Clinical Oncology <b>OR</b>            |             |
| routine care data <b>OR</b>  |     | JAMA oncology <b>OR</b>                |             |
| Emulation <b>OR</b>          |     | Lancet (London, England)               |             |
| Electronic health            |     |  |             |
| record                       |     |  |             |

700 Table S2 Detailed Search History PubMed on October 31st 2023

| Search | Query  | Results |
|--------|--|---------|
| #1     | Search: ("The New England journal of                 | 435,802 |
|        | medicine"[Journal]) OR ("BMJ (Clinical research      |         |
|        | ed.)" [Journal]) OR ("The Lancet. Oncology"          |         |
|        | [Journal]) OR ("JAMA" [Journal]) OR ("Journal of     |         |
|        | clinical oncology : official journal of the American |         |
|        | Society of Clinical Oncology" [Journal]) OR          |         |
|        | ("JAMA oncology"(Journal]) OR ("Lancet               |         |
|        | (London, England)"[Journal])                         |         |
| #2     | Search: "real-world evidence" [tiab] OR "Real-       | 103,854 |
|        | world data" [tiab] OR real-world[tiab] OR            |         |
|        | RWE[tiab] OR "routine data" [tiab] or "routine       |         |
|        | care data " [tiab] OR Emulation [tiab] OR            |         |
|        | "Electronic health record" [tiab]                    |         |

| #3 | Search: #1 AND #2                         | 387 |
|----|---|-----|
| #4 | Search: #1 AND #2 Filters: from 2018-2023 | 227 |

701

#### Supplementary S2 702

Table S3 provides a comprehensive overview of the extracted studies, including their 703 characteristics and limitations described in their respective discussion section. Note, that for 704 some publications (indicated with an asterisk) the category could not be clearly assigned, 705 706 especially in the case of Treatment Comparison and Safety and Risk Group Analysis. These 707 publications did not only compare the effectiveness of treatments but specifically compared the risk of adverse events between two or more treatments [34,37,40-42,45,47]. 708

All studies categorized into the Burden of Disease scenario were cohort studies except for 709 three studies [22,25,28] that were developing or validating a machine learning model to predict 710 711 certain endpoints using EHR data. Three studies [26,29,64] examined time-to-event outcomes using Cox regression as well as Kaplan-Meier estimator partly with inverse propensity weights. 712 Prevalence and incidences were analyzed in four studies [23,24,27,30]. The studies that were 713 assigned to the category Safety and Risk Group Analysis were mostly cohort studies, in 714 addition to two case-control studies and one cross-sectional cohort study [32,33]. Similar to 715 716 the category Burden of Disease, predominantly time-to-event outcomes were evaluated using 717 Kaplan-Meier estimation or Cox (proportional hazards) regression models [34,37,38,40-42,44–46]. In contrast, many studies have used propensity score methods such as matching 718 719 and weighting [32,34,37,40-42,45,46] or applied the concept of target trial emulation 720 [32,37,45]. Similar to the category Safety and Risk Group Analysis, most studies in the Treatment Comparison scenario examined time-to-event outcomes. They employed 721 722 propensity score methods such as matching and weighting or applied the concept of target 723 trial emulation. In addition to that, two studies used the clone method, a special form of emulating a target trial where each individual is cloned into both treatment groups, censored 724 patients according to their designated treatment strategy and weighted the uncensored to 725 726 avoid selection bias [9,50,55].

#### 727 Table S3 Overview of study characteristics and limitations

| Author                 | Study<br>Design | Aim of Study  | Outcome  | Methods   | Scop<br>e              | Count<br>ries               |                     |                       |                         |                    |                                 |                 |                          |                                     |  |
|------------------------|-----------------|---|--|---|------------------------|-----------------------------|---------------------|-----------------------|-------------------------|--------------------|---------------------------------|-----------------|--------------------------|-------------------------------------|--|
|                        |                 |   |  |   |                        |                             | Main B              | ias Cate              | gories                  |                    | Additional Bias Category        |                 |                          |                                     |  |
| Burden of d            | isease          |   | I  | I   | I                      | I                           | Confo<br>undin<br>g | Selec<br>tion<br>bias | Inform<br>ation<br>bias | Reporti<br>ng bias | Follow-<br>up<br>Challen<br>ges | Missing<br>Data | Coding<br>Challen<br>ges | Validati<br>on &<br>Data<br>quality | Operatio<br>nalization<br>or<br>availabilit<br>y of<br>variables |
| Beck et al.<br>[24]    | cohort<br>study | genetic<br>association  | prevalenc<br>e                                 | Poisson test  | multi-<br>cente<br>r   | USA                         |                     | x                     | x                       |                    |                                 |                 | x                        |                                     |  |
| Biccler et<br>al. [29] | cohort<br>study | relapse risk<br>and loss of<br>lifetime after<br>treatment          | relapse<br>risks,<br>survival                  | logistic<br>regression,<br>KM estimation,<br>Aalen-<br>Johansen<br>estimation | multi-<br>natio<br>nal | Nordi<br>c<br>count<br>ries | x                   |                       |                         |                    | x                               |                 |                          | x                                   |  |
| Canavan<br>et al. [21] | cohort<br>study | association of<br>EOL<br>treatment and<br>practice-level<br>factors | use of<br>EOL<br>therapy                       | adjusted<br>logistic<br>regression<br>with random<br>intercept                | natio<br>n-<br>wide    | USA                         | x                   | x                     | x                       | x                  |                                 | x               |                          |                                     | x  |
| Chang et<br>al. [30]   | cohort<br>study | genetic<br>association  | prevalenc<br>e                                 | adjusted Firth<br>logistic<br>regression                                      | multi-<br>cente<br>r   | USA                         |                     | x                     | x                       | x                  |                                 |                 |                          | x                                   |  |
| Coltin et<br>al. [64]  | cohort<br>study | burden of<br>surviving<br>disease                                   | cumulativ<br>e<br>incidence<br>of<br>mortality | time-to-event<br>analyses, Cox<br>model                                       | multi-<br>cente<br>r   | Cana<br>da                  |                     | x                     |                         |                    | x                               |                 |                          |                                     |  |

| Forrest et<br>al. [25]   | cohort<br>study | disease-<br>predictive ML                     | disease<br>prediction                      | random forest<br>model, model<br>evaluation:<br>AUROC,<br>Sensitivity,<br>Specificity,<br>PPV, NPV,<br>Brier score,<br>adj. linear -,<br>logistic -, and<br>Cox<br>regression | natio<br>n-<br>wide  | UK     |   | x | x |   |   | x |   |   |
|--------------------------|-----------------|---|--|---|----------------------|--------|---|---|---|---|---|---|---|---|
| Haas et al.<br>[27]      | cohort<br>study | impact and<br>effectiveness<br>of treatment   | prevalenc<br>e,<br>incidence<br>rate ratio | negative<br>binomial<br>regression  | natio<br>n-<br>wide  | Israel | x | x | x | x |   |   |   |   |
| Kamran et<br>al. [22]    | cohort<br>study | ML model<br>development                       | mortality,<br>treatment<br>events          | regularized<br>logistic<br>regression,<br>AUROC,<br>model<br>calibration  | multi-<br>cente<br>r | USA    | × |   |   |   |   |   |   | x |
| Manz et al.<br>[28]      | cohort<br>study | Validation of<br>ML Algorithm                 | mortality                                  | AUROC,<br>AUPRC,<br>scaled Brier<br>score, logistic<br>regression   | multi-<br>cente<br>r | USA    |   |   | x |   |   | x | x |   |
| Vasileiou<br>et al. [26] | cohort<br>study | hospital<br>admission<br>after<br>vaccination | hospital<br>admission                      | time-<br>dependent<br>Cox model &<br>Poisson<br>regression<br>with inverse<br>propensity<br>weights   | natio<br>n-<br>wide  | UK     | x | x |   |   | x |   |   |   |
| Witberg et<br>al. [23]   | cohort<br>study | frequency<br>and severity<br>of disease       | (cumulati<br>ve)<br>incidence              | KM estimation   | natio<br>n-<br>wide  | Israel |   | x | x |   |   | x |   |   |

|                                      |   | after<br>treatment   |   |  |                      |           |                     |                       |                         |                    |                                 |                 |                          |                                     |  |
|--------------------------------------|---|--|---|--|----------------------|-----------|---------------------|-----------------------|-------------------------|--------------------|---------------------------------|-----------------|--------------------------|-------------------------------------|--|
| Safety and F                         | Safety and Risk Group                                     |  |   |  |                      |           | Confo<br>undin<br>g | Selec<br>tion<br>bias | Inform<br>ation<br>bias | Reporti<br>ng bias | Follow-<br>up<br>Challen<br>ges | Missing<br>Data | Coding<br>Challen<br>ges | Validati<br>on &<br>Data<br>quality | Operatio<br>nalization<br>or<br>availabilit<br>y of<br>variables |
| Berry et al.<br>[44]                 | cohort<br>study   | genetic<br>association   | incidence,<br>prevalenc<br>e                                      | Cox<br>regression,<br>adj. logistic<br>regression        | multi-<br>cente<br>r | USA<br>UK | x                   | x                     | x                       |                    |                                 |                 |                          | x                                   |  |
| Chavez-<br>MacGrego<br>r et al. [43] | cohort<br>study   | outcome<br>comparison of<br>risk groups                            | morality,<br>ventilation<br>, ICU<br>stay,<br>hospitaliz<br>ation | adj. logistic<br>regression                              | multi-<br>cente<br>r | USA       | x                   | x                     |                         |                    |                                 |                 |                          |                                     | x  |
| Chemaitell<br>y et al. [46]          | cohort<br>studies   | treatment<br>effectiveness<br>among<br>children and<br>adolescents | incidence<br>rate,<br>cumulativ<br>e<br>incidence                 | 1:1 matching,<br>KM estimation,<br>Cox<br>regression     | natio<br>n-<br>wide  | Qatar     | x                   | x                     |                         | x                  |                                 |                 |                          |                                     |  |
| Cohen-<br>Stavi et al.<br>[32]       | cohort<br>study,<br>case-<br>control<br>study             | treatment<br>effectiveness<br>among<br>children                    | cumulativ<br>e<br>incidence                                       | target trail<br>emulation,<br>matching, KM<br>estimation | multi-<br>cente<br>r | Israel    | x                   |                       | x                       |                    | x                               |                 |                          |                                     |  |
| Damrauer<br>et al. [33]              | case-<br>control<br>study,<br>cross<br>sectional<br>study | genetic<br>association   | prevalenc<br>e  | adj. logistic<br>regressions                             | multi-<br>cente<br>r | USA       |                     | x                     | x                       |                    |                                 | x               | x                        |                                     |  |
| Deng et al.<br>[45]*                 | cohort<br>study   | comparative<br>effectiveness                                       | time to<br>event  | target trail<br>emulation,<br>inverse                    | natio<br>n-<br>wide  | USA       | x                   | x                     | x                       |                    | x                               | X               |                          |                                     | x  |

|                         |                         |   |  | probability of<br>treatment<br>weighting,<br>generalized<br>boosted<br>models for PS,<br>inverse<br>probability of<br>treatment<br>weighted<br>Kaplan-Meier<br>method, PS-<br>weighted Cox<br>regression |                        |  |   |   |   |   |   |   |   |   |   |
|-------------------------|-------------------------|---|--|--|------------------------|--|---|---|---|---|---|---|---|---|---|
| Filion et al.<br>[34]*  | cohort<br>study         | adverse event<br>association                        | major<br>adverse<br>events                               | time<br>conditional PS<br>using<br>conditional<br>logistic<br>regression, 1:1<br>matching, Cox<br>regression   | multi-<br>cente<br>r   | Cana<br>da<br>UK   | x | x | X | x | x |   |   |   | x |
| Forrest et<br>al. [35]  | cohort<br>study         | disease risk<br>associated<br>with gene<br>variants | risk<br>difference<br>between<br>prevalenc<br>e          | 2-sided<br>Fisher's exact<br>tests   | multi-<br>cente<br>r   | USA<br>UK  |   | x | x |   |   |   | x |   |   |
| Harstad et<br>al. [47]* | observatio<br>nal study | treatment<br>effectiveness                          | frequency<br>, relative<br>risk of<br>Adverse<br>Effects | logistic and<br>Cox<br>regression  | multi-<br>cente<br>r   | USA  | x | x |   |   | x |   |   | x |   |
| Li et al.<br>[36]       | cohort<br>study         | adverse event<br>association                        | incidence<br>rate  | descriptive<br>analyses  | multi-<br>natio<br>nal | Austr<br>alia<br>Franc<br>e<br>Germ<br>any<br>Japan<br>Nethe |   |   | X | x |   | x |   | x |   |

|                                |                 |                              |  |   |                           | rlands<br>Spain<br>UK<br>US                   |   |   |   |   |   |   |   |   |
|--------------------------------|-----------------|------------------------------|--|---|---------------------------|---|---|---|---|---|---|---|---|---|
| Lyu et al.<br>[37]*            | cohort<br>study | comparative<br>effectiveness | incidence  | target trail<br>emulation, PS-<br>matching, Cox<br>regression | natio<br>n-<br>wide       | UK  | х |   | x |   | x |   |   |   |
| Martin et<br>al. [38]          | cohort<br>study | therapy<br>evaluation        | time-to-<br>next-<br>treatment,<br>overall<br>survival | KM, Cox<br>regression   | natio<br>n-<br>wide       | USA   | x |   | x |   |   | x |   | x |
| Seymour<br>et al. [39]         | cohort<br>study | phenotype<br>derivation      | phenotyp<br>e<br>frequency<br>, mortality              | Multiple<br>imputation, k-<br>means<br>clustering             | single<br>-<br>cente<br>r | USA   |   | x | x |   |   | x |   |   |
| Song et al.<br>[65]            | cohort<br>study | comparative<br>effectiveness | disease<br>risk  | adj. logistic<br>regression                                   | natio<br>n-<br>wide       | USA   | x |   |   | x |   |   |   |   |
| Suchard et<br>al. [41]*        | cohort<br>study | comparative<br>effectiveness | relative<br>risk                                       | PS model,<br>matching, Cox<br>regression,<br>meta analysis    | multi-<br>natio<br>nal    | USA<br>South<br>Korea<br>Japan<br>Germ<br>any | x | x | × | x |   |   |   |   |
| Vinogrado<br>va et<br>al.[42]* | cohort<br>study | treatment<br>association     | hospital<br>admission<br>or death                      | PS, Cox<br>regression   | natio<br>n-<br>wide       | UK  | x |   | x | x |   |   |   | x |
| You et al.<br>[40]*            | cohort<br>study | treatment<br>association     | net<br>adverse<br>clinical<br>events                   | PS-matching,<br>Cox<br>regression                             | multi-<br>cente<br>r      | South<br>Korea<br>USA                         | x |   | x | x |   |   | x | x |

| Treatment Comparison     |                           |                              |  |   |                        |                             |   | Selec<br>tion<br>bias | Inform<br>ation<br>bias | Reporti<br>ng bias | Follow-<br>up<br>Challen<br>ges | Missing<br>Data | Coding<br>Challen<br>ges | Validati<br>on &<br>Data<br>quality | Operatio<br>nalization<br>or<br>availabilit<br>y of<br>variables |
|--------------------------|---------------------------|------------------------------|--|---|------------------------|-----------------------------|---|-----------------------|-------------------------|--------------------|---------------------------------|-----------------|--------------------------|-------------------------------------|--|
| Andersson<br>et al. [53] | cohort<br>study           | comparative<br>effectiveness | hospital<br>admission<br>, death   | target trail<br>emulation, PS-<br>matching,<br>inverse<br>probability of<br>treatment<br>weights, KM  | multi-<br>natio<br>nal | Nordi<br>c<br>count<br>ries | x | x                     | x                       |                    |                                 |                 |                          |                                     |  |
| Deputy et<br>al. [54]    | case-<br>control<br>study | vaccine<br>effectiveness     | associatio<br>n<br>between<br>vaccinatio<br>n status<br>and case<br>patient or<br>control<br>patient<br>status | matching,<br>conditional<br>logistic<br>regression  | natio<br>n-<br>wide    | USA                         | x | x                     | x                       |                    |                                 |                 |                          |                                     |  |
| Kim et al.<br>[49]       | cohort<br>study           | treatment<br>effectiveness   | time to<br>cardiovas<br>cular<br>events  | PS-matching,<br>stratified Cox<br>regression  | natio<br>n-<br>wide    | South<br>Korea              | x | x                     | x                       | x                  |                                 |                 |                          |                                     |  |
| Mahévas<br>et al. [51]   | case-<br>control<br>study | treatment<br>effectiveness   | survival   | inverse<br>probability of<br>treatment<br>weighting, Cox<br>regression,<br>KM, multiple<br>imputation | multi-<br>cente<br>r   | Franc<br>e                  | X | x                     |                         |                    |                                 |                 |                          |                                     | x  |
| Marafino<br>et al. [58]  | cohort<br>study           | intervention<br>association  | mortality,<br>readmissi<br>on  | target-trail<br>emulation,<br>generalized<br>linear mixed<br>effects                                  | multi-<br>cente<br>r   | USA                         | x | x                     |                         |                    |                                 |                 | x                        |                                     |  |

|                        |   |                                   |   | models,<br>difference-in-<br>difference<br>analysis  |                        |              |   |   |   |   |   |   |   |   |
|------------------------|---|-----------------------------------|---|--|------------------------|--------------|---|---|---|---|---|---|---|---|
| Rentsch et<br>al. [52] | cohort<br>study                               | early<br>treatment<br>association | mortality   | inverse<br>probability of<br>treatment<br>weighted KM,<br>Cox<br>regression                        | natio<br>n-<br>wide    | USA          | x | x | x |   |   | x | x | x |
| Wang et<br>al. [8]     | cohort<br>study                               | RCT<br>comparison                 | time to<br>event  | target trail<br>emulation, PS<br>matching, Cox<br>regression                                       | natio<br>n-<br>wide    | USA          | x | x |   | x | x |   |   |   |
| Wong et<br>al. [57]    | cohort<br>study,<br>case-<br>control<br>study | comparative<br>effectiveness      | mortality,<br>hospital<br>admission<br>,<br>progressi<br>on   | propensity<br>score<br>matching, Cox<br>regression,<br>conditional<br>logistic<br>regression       | territo<br>ry-<br>wide | Hong<br>Kong | X | x | X |   |   | x |   |   |
| Xie et al.<br>[50]     | cohort<br>study                               | treatment<br>association          | relative<br>risk,<br>event<br>rate,<br>absolute<br>risk<br>reduction:<br>hospital<br>admission<br>, death | target trail<br>emulation,<br>clone method,<br>inverse<br>probability of<br>censoring<br>weight    | natio<br>n-<br>wide    | USA          | x |   | x |   |   |   |   |   |
| Xie et al.<br>[55]     | cohort<br>study                               | treatment<br>effectiveness        | relative<br>risk,<br>event<br>rate,<br>absolute<br>risk<br>reduction:                                     | target trail<br>emulation,<br>inverse<br>probability<br>weighting,<br>clone method,<br>weighted KM | natio<br>n-<br>wide    | USA          | X | x | X |   |   |   |   |   |

|                      |                 |                              | hospital<br>admission<br>, death |                    |             |    |   |   |   |  |  |   |
|----------------------|-----------------|------------------------------|----------------------------------|--------------------|-------------|----|---|---|---|--|--|---|
| Zheng et<br>al. [56] | cohort<br>study | comparative<br>effectiveness |                                  | Cox<br>regression, | natio<br>n- | UK | х | х | x |  |  | x |
|                      |                 |                              | , death                          | PS- weighting      | wide        |    |   |   |   |  |  |   |

- Abbreviation: KM... Kaplan-Meier, PS... Propensity Score, EOL... End-of-Life, ICU... Intensive Care Unit, ML... Machine Learning, AUROC...
   Area under the receiver operating curve, AUPRC... Area under the precision-recall curve
- \* This indicates publications that were not uniquely categorizable into the main scenarios. Specifically, they did not only compare the effectiveness
- of treatments but compared the risk of adverse events between two or more treatments